Tocilizumab in Coronavirus Disease 2019: Give It Time!
作者信息
Richier Quentin, Plaçais Léo, Lacombe Karine, Hermine Olivier
机构信息
Department of Infectious Diseases, Saint Antoine Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France.
University of Paris, Paris, France.
出版信息
Clin Infect Dis. 2021 Dec 16;73(12):2368-2369. doi: 10.1093/cid/ciab081.
Abstract
摘要
相似文献
1
Tocilizumab in Coronavirus Disease 2019: Give It Time!托珠单抗治疗冠状病毒病2019：给它一些时间！
Clin Infect Dis. 2021 Dec 16;73(12):2368-2369. doi: 10.1093/cid/ciab081.
2
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
3
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
4
Tocilizumab; A Potential Remedy Against The Ever-Evolving Threat Of Coronavirus-2 (SARS-Cov-2).托珠单抗：应对不断演变的新型冠状病毒2（SARS-CoV-2）威胁的一种潜在疗法。
J Pak Med Assoc. 2023 Aug;73(8):1776-1777. doi: 10.47391/JPMA.8551.
5
Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.接受托珠单抗治疗的2019冠状病毒病（COVID-19）患者的结局异质性
Clin Infect Dis. 2022 Apr 28;74(8):1504. doi: 10.1093/cid/ciab816.
6
Impact of Tocilizumab on the Mortality of Patients With Coronavirus Disease 2019.托珠单抗对2019冠状病毒病患者死亡率的影响。
Clin Infect Dis. 2021 Jun 15;72(12):e1156-e1157. doi: 10.1093/cid/ciaa1738.
7
Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019.对2019冠状病毒病住院患者使用托珠单抗提出质疑。
Chest. 2021 May;159(5):2115-2116. doi: 10.1016/j.chest.2020.11.069.
8
The Misleading "Pooled Effect Estimate" of Crude Data from Observational Studies at Critical Risk of Bias: The Case of Tocilizumab in Coronavirus Disease 2019 (COVID-19).存在偏倚重大风险的观察性研究原始数据的误导性“合并效应估计值”：以托珠单抗治疗2019冠状病毒病（COVID-19）为例
Clin Infect Dis. 2021 Jun 15;72(12):e1154-e1155. doi: 10.1093/cid/ciaa1735.
9
Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID).托珠单抗与皮质类固醇的早期联合应用：重症冠状病毒病（COVID）抗炎治疗的升级
Clin Infect Dis. 2021 May 4;72(9):1682-1683. doi: 10.1093/cid/ciaa910.
10
Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See.托珠单抗治疗重症2019冠状病毒病的成本效益：看或不看
Clin Infect Dis. 2021 Dec 6;73(11):2119-2120. doi: 10.1093/cid/ciab459.
引用本文的文献
1
Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia.确定托珠单抗在新冠病毒肺炎治疗中地位的随机试验系统评价和亚组荟萃分析
Infect Dis Ther. 2021 Sep;10(3):1195-1213. doi: 10.1007/s40121-021-00488-6. Epub 2021 Jul 11.
2
The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer.全身性炎症反应：直击 COVID-19 与癌症之间的危险关联。
ESMO Open. 2021 Jun;6(3):100123. doi: 10.1016/j.esmoop.2021.100123. Epub 2021 Apr 8.
3
Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.托珠单抗治疗 COVID-19 肺炎：基于随机对照试验的叙述性综述的实用建议。
Rev Med Virol. 2022 Jan;32(1):e2239. doi: 10.1002/rmv.2239. Epub 2021 Apr 21.
Zotero 插件